WO2009054454A1 - カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 - Google Patents
カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 Download PDFInfo
- Publication number
- WO2009054454A1 WO2009054454A1 PCT/JP2008/069235 JP2008069235W WO2009054454A1 WO 2009054454 A1 WO2009054454 A1 WO 2009054454A1 JP 2008069235 W JP2008069235 W JP 2008069235W WO 2009054454 A1 WO2009054454 A1 WO 2009054454A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signaling
- regulator
- active ingredient
- therapeutic agent
- toll
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
【課題】TLRのシグナル伝達の調整剤を提供すること。 【解決手段】(2S,3S)-3-[[(1S)-1-イソブトキシメチル-3-メチルブチル]カルバモイル]オキシラン-2-カルボン酸モノナトリウム)などのカテプシン阻害剤を有効成分として含有する製剤をTLRのシグナル伝達の調整剤、TLRのシグナル伝達が関与する疾患の治療の治療剤、Th17細胞の誘導が関与する疾患の治療剤、IL-6、IL-12、IL-17又はIL-23の産生が関与する疾患の治療剤、並びに全身性エリテマトーデス、ループス腎炎、クローン病、乾癬、又は急性散在性脳脊髄炎の治療剤として使用する。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009538249A JPWO2009054454A1 (ja) | 2007-10-24 | 2008-10-23 | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 |
EP08841616A EP2216047A4 (en) | 2007-10-24 | 2008-10-23 | REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE |
US12/739,497 US20100331545A1 (en) | 2007-10-24 | 2008-10-23 | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-276937 | 2007-10-24 | ||
JP2007276937 | 2007-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009054454A1 true WO2009054454A1 (ja) | 2009-04-30 |
Family
ID=40579556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/069235 WO2009054454A1 (ja) | 2007-10-24 | 2008-10-23 | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100331545A1 (ja) |
EP (1) | EP2216047A4 (ja) |
JP (1) | JPWO2009054454A1 (ja) |
WO (1) | WO2009054454A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200230251A1 (en) * | 2014-08-14 | 2020-07-23 | Friedrich-Schiller-Universitaet Jena | Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects |
EP3831400A1 (en) * | 2014-09-18 | 2021-06-09 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06336428A (ja) * | 1993-05-27 | 1994-12-06 | Takeda Chem Ind Ltd | 免疫抑制剤 |
WO1996030354A1 (fr) | 1995-03-31 | 1996-10-03 | Nippon Chemiphar Co., Ltd. | Derives d'acide epoxysuccinique |
WO1997021694A1 (fr) | 1995-12-12 | 1997-06-19 | Taiho Pharmaceutical Co., Ltd. | Derives d'epoxysuccinamides ou sels de ces derives, et medicaments les contenant |
WO1998047887A1 (fr) | 1997-04-18 | 1998-10-29 | Taiho Pharmaceutical Co., Ltd. | Nouveaux derives d'epoxysuccinamide et sels associes |
WO1999011640A1 (fr) | 1997-09-04 | 1999-03-11 | Nippon Chemiphar Co., Ltd. | Derives d'epoxysuccinamide |
JPH11263783A (ja) | 1998-01-09 | 1999-09-28 | Taisho Pharmaceut Co Ltd | エポキシスクシナム酸誘導体 |
JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
JP2000509376A (ja) * | 1996-04-22 | 2000-07-25 | マサチューセッツ インスティテュート オブ テクノロジー | カテプシンsの阻害を通しての免疫応答の抑制 |
WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
WO2001058886A1 (en) | 2000-02-10 | 2001-08-16 | Novartis Ag | Dipeptide nitrile cathepsin k inhibitors |
WO2001070232A1 (en) | 2000-03-21 | 2001-09-27 | Smithkline Beecham Corporation | Protease inhibitors |
JP2002539190A (ja) * | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | プロテアーゼ阻害剤としての新規化合物および組成物 |
JP2003519125A (ja) * | 1999-12-24 | 2003-06-17 | エフ.ホフマン−ラ ロシュ アーゲー | カテプシンk阻害剤としてのニトリル誘導体 |
WO2003053331A2 (en) | 2000-11-22 | 2003-07-03 | Smithkline Beecham Corporation | Protease inhibitors |
WO2003075836A2 (en) | 2002-03-05 | 2003-09-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
WO2003091202A1 (fr) | 2002-04-25 | 2003-11-06 | Ono Pharmaceutical Co., Ltd. | Composes derives de dicetohydrazine et medicaments contenant ces composes comme ingredient actif |
JP2004517918A (ja) | 2000-10-18 | 2004-06-17 | イミュネックス・コーポレーション | Il−17アンタゴニストを使用する慢性関節リューマチの治療法 |
JP2004526662A (ja) * | 2000-04-18 | 2004-09-02 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
WO2004108661A1 (en) | 2003-06-04 | 2004-12-16 | Axys Pharmaceuticals | Amidino compounds as cysteine protease inhibitors |
WO2005000800A1 (en) | 2003-06-30 | 2005-01-06 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
JP2005501017A (ja) * | 2001-06-08 | 2005-01-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆的阻害剤として有効な新規なニトリル |
WO2005066180A1 (en) | 2004-01-08 | 2005-07-21 | Medivir Ab | Cysteine protease inhibitors |
JP2006505526A (ja) * | 2002-08-22 | 2006-02-16 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
JP2006514004A (ja) | 2002-10-30 | 2006-04-27 | ジェネンテック・インコーポレーテッド | Il−17産生の阻害 |
JP2006519768A (ja) * | 2003-03-13 | 2006-08-31 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンsインヒビター |
JP2006520781A (ja) | 2003-03-10 | 2006-09-14 | シェーリング コーポレイション | Il−23アゴニストおよびil−23アンタゴニスト;関連試薬の使用 |
WO2006109045A2 (en) * | 2005-04-09 | 2006-10-19 | Fusion Antibodies Limited | Cathepsin s antibody |
WO2007025774A2 (en) | 2005-09-02 | 2007-03-08 | Glaxo Group Limited | Cysteine protease inhibitors |
JP2007511593A (ja) | 2003-11-21 | 2007-05-10 | セルテック アール アンド ディ リミテッド | Il−17活性阻害による多発性硬化症を治療するための方法 |
JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター(tlr)アンタゴニスト |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5556853A (en) * | 1993-10-29 | 1996-09-17 | Takeda Chemical Industries, Ltd. | Epoxysuccinic acid derivatives |
BRPI0412769A (pt) * | 2003-07-21 | 2006-09-26 | Novartis Ag | combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor |
-
2008
- 2008-10-23 WO PCT/JP2008/069235 patent/WO2009054454A1/ja active Application Filing
- 2008-10-23 EP EP08841616A patent/EP2216047A4/en not_active Withdrawn
- 2008-10-23 JP JP2009538249A patent/JPWO2009054454A1/ja active Pending
- 2008-10-23 US US12/739,497 patent/US20100331545A1/en not_active Abandoned
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06336428A (ja) * | 1993-05-27 | 1994-12-06 | Takeda Chem Ind Ltd | 免疫抑制剤 |
WO1996030354A1 (fr) | 1995-03-31 | 1996-10-03 | Nippon Chemiphar Co., Ltd. | Derives d'acide epoxysuccinique |
WO1997021694A1 (fr) | 1995-12-12 | 1997-06-19 | Taiho Pharmaceutical Co., Ltd. | Derives d'epoxysuccinamides ou sels de ces derives, et medicaments les contenant |
JP2000509376A (ja) * | 1996-04-22 | 2000-07-25 | マサチューセッツ インスティテュート オブ テクノロジー | カテプシンsの阻害を通しての免疫応答の抑制 |
WO1998047887A1 (fr) | 1997-04-18 | 1998-10-29 | Taiho Pharmaceutical Co., Ltd. | Nouveaux derives d'epoxysuccinamide et sels associes |
WO1999011640A1 (fr) | 1997-09-04 | 1999-03-11 | Nippon Chemiphar Co., Ltd. | Derives d'epoxysuccinamide |
JPH11263783A (ja) | 1998-01-09 | 1999-09-28 | Taisho Pharmaceut Co Ltd | エポキシスクシナム酸誘導体 |
JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
JP2002539190A (ja) * | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | プロテアーゼ阻害剤としての新規化合物および組成物 |
JP2003519125A (ja) * | 1999-12-24 | 2003-06-17 | エフ.ホフマン−ラ ロシュ アーゲー | カテプシンk阻害剤としてのニトリル誘導体 |
WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
WO2001058886A1 (en) | 2000-02-10 | 2001-08-16 | Novartis Ag | Dipeptide nitrile cathepsin k inhibitors |
WO2001070232A1 (en) | 2000-03-21 | 2001-09-27 | Smithkline Beecham Corporation | Protease inhibitors |
JP2004526662A (ja) * | 2000-04-18 | 2004-09-02 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
JP2004517918A (ja) | 2000-10-18 | 2004-06-17 | イミュネックス・コーポレーション | Il−17アンタゴニストを使用する慢性関節リューマチの治療法 |
WO2003053331A2 (en) | 2000-11-22 | 2003-07-03 | Smithkline Beecham Corporation | Protease inhibitors |
JP2005501017A (ja) * | 2001-06-08 | 2005-01-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆的阻害剤として有効な新規なニトリル |
WO2003075836A2 (en) | 2002-03-05 | 2003-09-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
WO2003091202A1 (fr) | 2002-04-25 | 2003-11-06 | Ono Pharmaceutical Co., Ltd. | Composes derives de dicetohydrazine et medicaments contenant ces composes comme ingredient actif |
JP2006505526A (ja) * | 2002-08-22 | 2006-02-16 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
JP2006514004A (ja) | 2002-10-30 | 2006-04-27 | ジェネンテック・インコーポレーテッド | Il−17産生の阻害 |
JP2006520781A (ja) | 2003-03-10 | 2006-09-14 | シェーリング コーポレイション | Il−23アゴニストおよびil−23アンタゴニスト;関連試薬の使用 |
JP2006519768A (ja) * | 2003-03-13 | 2006-08-31 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンsインヒビター |
WO2004108661A1 (en) | 2003-06-04 | 2004-12-16 | Axys Pharmaceuticals | Amidino compounds as cysteine protease inhibitors |
JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター(tlr)アンタゴニスト |
WO2005000800A1 (en) | 2003-06-30 | 2005-01-06 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
JP2007511593A (ja) | 2003-11-21 | 2007-05-10 | セルテック アール アンド ディ リミテッド | Il−17活性阻害による多発性硬化症を治療するための方法 |
WO2005066180A1 (en) | 2004-01-08 | 2005-07-21 | Medivir Ab | Cysteine protease inhibitors |
WO2006109045A2 (en) * | 2005-04-09 | 2006-10-19 | Fusion Antibodies Limited | Cathepsin s antibody |
WO2007025774A2 (en) | 2005-09-02 | 2007-03-08 | Glaxo Group Limited | Cysteine protease inhibitors |
Non-Patent Citations (13)
Title |
---|
ASAGIRI M. ET AL.: "Cathepsin K-Dependent Toll- Like Receptor 9 Signaling Revealed inExperimental Arthritis", SCIENCE, vol. 319, no. 5863, 1 February 2008 (2008-02-01), pages 624 - 627, XP008135679 * |
C.S. LI ET AL., BIOORG., MED. CHEM. LETT., vol. 16, 2006, pages 1985 - 1989 |
H. HEMMI ET AL., NATURE, vol. 408, 2000, pages 740 |
J. ROBICHAUD ET AL., J. MED. CHEM., vol. 46, 2003, pages 3709 - 3727 |
K. INABA ET AL., J. EXP. MED., vol. 176, 1992, pages 1693 |
K. SATO ET AL., NAT MED, vol. 12, 2006, pages 1410 |
N. KATUMUMA ET AL., FEBS LETT., vol. 458, 1999, pages 6 - 10 |
P. SAFTIG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13453 |
R.W. MARQUIS ET AL., J. MED. CHEM., vol. 44, 2001, pages 1380 - 1395 |
See also references of EP2216047A4 * |
T. OTSUKA ET AL., J. ANTIBIOT., vol. 52, 1999, pages 536 - 541 |
T. YASUMA ET AL., J. MED. CHEM., vol. 41, 1998, pages 4301 - 4308 |
TSUKUBA T. ET AL.: "Cathepsin E-deficient mice show increased susceptibility to bacterialinfection associated with the decreased expression of multiple cellsurface Toll-like receptors", JOURNAL OF BIOCHEMISTRY, vol. 140, no. 1, 2006, pages 57 - 66, XP008135678 * |
Also Published As
Publication number | Publication date |
---|---|
EP2216047A1 (en) | 2010-08-11 |
JPWO2009054454A1 (ja) | 2011-03-03 |
US20100331545A1 (en) | 2010-12-30 |
EP2216047A4 (en) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007127263A3 (en) | Therapeutic uses of urolithins | |
MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
IL201479A0 (en) | Titration of tapentadol | |
TW200626068A (en) | Active compounds for seed treatment | |
WO2011014661A3 (en) | Liver x receptor agonists | |
WO2007025613A3 (en) | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | |
IL188475A0 (en) | Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors | |
WO2011005595A3 (en) | 2-5a analogs and their methods of use | |
MX2009011878A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. | |
WO2006096518A3 (en) | Improved gacyclidine formulations | |
WO2011156557A3 (en) | Compounds active at the neurotensin receptor | |
EA201300672A1 (ru) | Шоколадная масса | |
WO2009071082A3 (en) | Rna antagonist compounds for the modulation of pik3ca expression | |
WO2008135819A8 (en) | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide | |
WO2008053334A3 (en) | An improved process for preparing rosuvastatin calcium | |
WO2010007522A8 (en) | Rna antagonists targeting gli2 | |
WO2007082262A3 (en) | Novel compounds | |
CA2527093A1 (en) | 3-fluoro-piperidines as nmda/nr2b antagonists | |
TW200719885A (en) | Prophylactic or therapeutic agent for depression or anxiety disorder | |
FR2938777B1 (fr) | Catalyseur en coquille, procede de preparation et utilisation de ce catalyseur. | |
TW200626140A (en) | Preventing vertical endoparasite infections | |
WO2009054454A1 (ja) | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 | |
FR2927900B1 (fr) | Procede de preparation d'alpha-aminoacetals optiquement actifs. | |
WO2009014127A1 (ja) | 自己抗体の産生に関連する疾患の予防又は治療のための組成物 | |
WO2011000945A3 (en) | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08841616 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009538249 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008841616 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12739497 Country of ref document: US |